CAC
TBPH icon

Cowen and Company’s Theravance Biopharma TBPH Stock Holding History

Cowen and Company’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,622
Closed -$260K – 633
2020
Q4 		$260K Buy
+14,622
New +$262K 0.02% 158
2020
Q3 		– Sell
-13,664
Closed -$287K – 508
2020
Q2 		$287K Buy
+13,664
New +$351K 0.05% 176

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Cowen and Company's TBPH Position: Q1 2021 in Review

Cowen and Company sold out of Theravance Biopharma (TBPH) in Q1 2021, closing a stake of 14,622 shares — an estimated $260K sold.

Cowen and Company first reported a position in TBPH in Q2 2020 and held it in 2 quarters. The position peaked at $287K in Q2 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q1 2021.

  • Cowen and Company reported no remaining Theravance Biopharma position as of Q1 2021 after selling out during the quarter.
  • Cowen and Company sold 14,622 Theravance Biopharma shares in Q1 2021, an estimated $260K.
  • Cowen and Company first reported a position in Theravance Biopharma in Q2 2020 and held it in 2 quarters.
  • Cowen and Company's Theravance Biopharma position peaked at $287K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2021.

Based on Cowen and Company's 13F filing for Q1 2021, filed 4 May 2021.